<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085059</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-11011</org_study_id>
    <secondary_id>EORTC-11011</secondary_id>
    <nct_id>NCT00085059</nct_id>
  </id_info>
  <brief_title>Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Early Phase II Study On BNCT In Metastatic Malignant Melanoma Using The Boron Carrier BPA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Boron neutron capture therapy using boronophenylalanine-fructose complex may kill&#xD;
      tumor cells without harming normal tissue.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well boron neutron capture therapy using&#xD;
      boronophenylalanine-fructose complex works in treating patients with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the therapeutic activity and efficacy of boron neutron capture therapy using&#xD;
           boronophenylalanine-fructose complex in patients with metastatic melanoma.&#xD;
&#xD;
        -  Determine the objective local response in patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the duration of local response and time to local progression in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the dose-response relationship at the per-lesion level in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive boronophenylalanine-fructose complex IV over 90 minutes followed by boron&#xD;
      neutron capture therapy on days 1 and 2.&#xD;
&#xD;
      Patients are followed at 1 and 6 weeks and then every 8 weeks thereafter. In the event of&#xD;
      disease progression, patients are followed every 3 months for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16-24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best response to treatment as measured by RECIST every 8 weeks at completion of study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured every 8 weeks at completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of local response as measured by Kaplan Meier every 8 weeks after completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local progression measured every 8 weeks after completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity as measured by Common Toxicity Criteria AE v 3.0 1- 6 weeks after completion of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity as measured by RTOG and EORTC week 6 and thereafter upon completion of study treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>boronophenylalanine-fructose complex</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed melanoma&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
                    -  Brain metastases, skin metastases, or soft tissue metastases of the head and&#xD;
                       neck or the extremities&#xD;
&#xD;
               -  Accessible lesion(s) for boron neutron capture therapy (BNCT)&#xD;
&#xD;
               -  No clear progression of disease at other sites than the ones intended for&#xD;
                  treatment with surgery and/or BNCT&#xD;
&#xD;
          -  Measurable disease by MRI within the past 4 weeks&#xD;
&#xD;
               -  Lesion(s) ≥ 10 mm in diameter&#xD;
&#xD;
          -  Indication for palliative radiotherapy that is intended to be delivered as BNCT&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.5 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  Transaminases ≤ 2.5 times ULN*&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN* NOTE: *Unless due to reversible reaction to&#xD;
             antiseizure medication&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.5 times ULN&#xD;
&#xD;
          -  Blood urea nitrogen ≤ 2.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No newly diagnosed or unstable angina pectoris&#xD;
&#xD;
          -  No uncontrolled arrhythmias&#xD;
&#xD;
          -  No uncontrolled conduction defects&#xD;
&#xD;
          -  No recent coronary artery disease&#xD;
&#xD;
          -  No other severe heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe pulmonary disease, including severe obstructive or restrictive lung disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No history of phenylketonuria&#xD;
&#xD;
          -  No severe gastrointestinal disease&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No uncontrolled endocrine disease&#xD;
&#xD;
          -  No pre-existing serious mental or organic brain disease (e.g., epilepsy)&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
          -  Able to travel to the Netherlands via public transportation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunologic or biologic therapy&#xD;
&#xD;
          -  No concurrent colony-stimulating factors (e.g., epoetin alfa or filgrastim [G-CSF])&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to site(s) proposed for study treatment&#xD;
&#xD;
          -  No other concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior anti-tumor therapy (excluding alopecia and sensitive&#xD;
             peripheral neuropathy ≤ grade 2)&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Wittig</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaetsklinikum Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Wittig A, Moss RL, Stecher-Rasmussen F, Appelman K, Rassow J, Roca A, Sauerwein W. Neutron activation of patients following boron neutron capture therapy of brain tumors at the high flux reactor (HFR) Petten (EORTC Trials 11961 and 11011). Strahlenther Onkol. 2005 Dec;181(12):774-82.</citation>
    <PMID>16362787</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

